01—Abstract
Summary
Summary of the 8-K filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.
AMETEK reported first quarter 2025 results (three months ended March 31, 2025) that were solid overall.
Sales were $1.73 billiona, essentially flat versus the prior year ($1.736 billion), while operating income rose to $454.8 million from $417.2 million on a GAAP basis. Operating margin was 26.3%, up from 24.0% GAAP (and up 60 basis points versus prior-year adjusted results). GAAP diluted EPS was $1.52 versus $1.34 a year earlier, and adjusted diluted EPS was $1.75, up 7% from $1.64.
Free cash flow conversion was 112% of net income. Management cited high single-digit orders growth and strong margin expansion, with the Electromechanical Group delivering record sales of $588.3 millionb and a 21.9% operating margin. The quarter's GAAP comparisons are flattered by the absence of Paragon integration costs in 2025 (which totaled $29.2 million in Q1 2024).
Interest expense fell sharply to $19.0 millionc from $35.3 million, and reported net income rose to $351.8 million from $310.9 million. Electronic Instruments Group sales declined 1% to $1.14 billion, but its operating margin expanded to 31.0%. The balance sheet strengthened, with cash rising to $399 million, short-term debt falling to $472 million from $654 million, and stockholders' equity increasing to $9.97 billion.
Looking ahead, AMETEK reaffirmed its full-year 2025 outlook for overall sales growth of low single digits and adjusted EPS of $7.02 to $7.18d, up 3% to 5%. Management acknowledged rising uncertainty from global trade dynamics and tariffs but expects mitigation actions to offset the headwinds. The company characterized first-quarter earnings as solidly above its expectations.
02—Key points
Key Highlights
- Q1 2025 sales of $1.73 billion were roughly flat year over year, with the Electromechanical Group reaching a record $588.3 million (up 2%) offsetting a 1% decline in Electronic Instruments.
- GAAP operating income rose about 9% to $454.8 million, and operating margin expanded to 26.3% from 24.0%, reflecting the lapping of 2024 Paragon integration costs.
- Adjusted diluted EPS of $1.75 was up 7% from $1.64; GAAP diluted EPS rose to $1.52 from $1.34.
- Free cash flow was $394.5 million, representing 112% conversion of net income, though down from 123% in the prior-year period.
- Interest expense dropped to $19.0 million from $35.3 million, a meaningful contributor to GAAP net income growth of about 13%.
- Management reaffirmed 2025 guidance for low single-digit sales growth and adjusted EPS of $7.02 to $7.18, while flagging tariff and trade-related uncertainty.
- Balance sheet improved: short-term borrowings fell to $472 million from $654 million and stockholders' equity rose to $9.97 billion, with cash up to $399 million.
03—Questions
Frequently Asked Questions
Did AMETEK's first-quarter 2025 results show meaningful top-line growth?
Not really. Net sales were $1.73 billion, essentially flat versus $1.74 billion in Q1 2024. Growth came mainly from margin expansion and lower interest expense rather than revenue, with EMG growing 2% and EIG declining 1%.
Why did GAAP earnings grow faster than sales?
Q1 2024 included $29.2 million of Paragon integration costs that did not recur in 2025, lifting GAAP operating income by about 9%. Interest expense also fell by roughly $16 million, which boosted pretax income and net income.
Is the 2025 outlook changing?
No. Management reiterated its full-year outlook of low single-digit sales growth and adjusted EPS of $7.02 to $7.18, up 3% to 5% over 2024. It acknowledged greater uncertainty from global trade and tariffs but expects mitigation actions to offset the headwinds.
How strong is AMETEK's cash generation?
Operating cash flow was $417.5 million and free cash flow was $394.5 million in the quarter. Free cash flow conversion of 112% of net income is strong, although it declined from 123% a year earlier and capital expenditures were modest at $23.1 million.
What is the outlook for the Electromechanical Group's Paragon Medical business?
Management highlighted a sizeable increase in Paragon Medical orders in the quarter and cited solid sales and orders growth at EMG. This is an encouraging sign for the segment's momentum, though the filing does not quantify the order increase.
04—Continue